申请人:Pfizer Inc.
公开号:US05026715A1
公开(公告)日:1991-06-25
2-Guanidino-4-arylthiazole compounds of the formula ##STR1## a pharmaceutically acceptable cationic or acid addition salt thereof wherein R.sup.1 is hydrogen, (C.sub.1 -C.sub.10)alkyl, optionally substituted phenyl or certain optionally substituted aralkyl groups; R.sup.2 is hydrogen or (C.sub.1 -C.sub.4)alkyl, and Ar is certain optionally substituted pyrrolyl or indolyl groups; method for their use in treatment of gastric ulcers, by inhibition of parietal cell H.sup.+ /K.sup.+ ATPase, and antiinflammatory conditions in combination with piroxicam, for use in mammals, and pharmaceutical compositions containing said compounds.
式为##STR1##的2-鸟氨酸基-4-芳基噻唑化合物及其药学上可接受的阳离子或酸加合物盐,其中R.sup.1为氢、(C.sub.1 -C.sub.10)烷基、可选择取代苯基或某些可选择取代的芳基烷基基团;R.sup.2为氢或(C.sub.1 -C.sub.4)烷基,Ar为某些可选择取代的吡咯基或吲哚基团;其在治疗胃溃疡中的应用方法,通过抑制壁细胞H.sup.+ /K.sup.+ ATP酶,以及与哌替考结合用于治疗哮喘炎症状的条件,用于哺乳动物,并含有上述化合物的药物组合物。